Figure 2 Algorithm for immunosuppressive treatment

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Electromechanical properties of OIHPs

Figure 6 Selected examples of TERS applications in material systems

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Role of innate lymphoid cells (ILCs) in steady state,

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Figure 6 Effects of adiponectin on podocyte function

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Expression of complement activation products in renal samples

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 2 The network of chronic diseases and their mutual influences

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 Proposed therapy scheme for anti-LGI1 encephalitis

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Anatomical patterns of neuropathy

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 6 Combining population-wide and high-risk strategies

Figure 1 Ischaemic stroke prevalence and mortality

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Serum phosphate level is associated with

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 The VEGF family of growth factors

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 The relationship between health fitness and pathogen load

Figure 2 Cellular pathways implicated in CIPN

Figure 4 Diagnosing neuropathic pain

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Proposed approach to treating myositis-associated interstitial lung disease Figure 2 | Proposed approach to treating myositis-associated interstitial.

Figure 4 4D printing schemes and time-evolving structure geometries

Nat. Rev. Neurol. doi: /nrneurol

Kaplan–Meier curves for the time until myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-positive conversion (A: MPO-ANCA, B: proteinase 3.

Figure 2 Network connections of the hypothalamus

Presentation transcript:

Figure 2 Algorithm for immunosuppressive treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides Figure 2 | Algorithm for immunosuppressive treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.Standard induction treatment is with cyclophosphamide and glucocorticoids, with alternatives for milder or more severe disease. Standard maintenance treatment is with azathioprine or methotrexate, which should be continued for longer than the glucocorticoids. Modified with permission from Nature Publishing Group © Schönermarck, U. et al. Nat. Rev. Nephrol. 10, 25–36 (2014). Collins, M. P. & Hadden, R. D. (2017) The nonsystemic vasculitic neuropathies Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.42